<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0002055'>Diabetes</z:mp> Care Austria was a nationwide data acquisition of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> treatment at Austrian general practitioners </plain></SENT>
<SENT sid="1" pm="."><plain>A total of 5,385 general practitioners were contacted in the end of 2009; finally, 101 agreed to participate in the data collection </plain></SENT>
<SENT sid="2" pm="."><plain>Out of <z:hpo ids='HP_0000001'>all</z:hpo> 9 Austrian provinces, a cross-sectional sample of 1.513 type 2 diabetic patients was investigated </plain></SENT>
<SENT sid="3" pm="."><plain>Demographic data, <z:mp ids='MP_0002055'>diabetes</z:mp> treatment, quality of <z:mp ids='MP_0002055'>diabetes</z:mp> control as well as micro- and macrovascular complications were analysed with respect to <z:mp ids='MP_0002055'>diabetes</z:mp> duration, categorised into 6 classes </plain></SENT>
<SENT sid="4" pm="."><plain>A total of 1.513 type 2 diabetic patients with a mean age of 65.4 ± 10.7 years and a mean <z:mp ids='MP_0002055'>diabetes</z:mp> duration of 8.7 ± 7.3 years were analysed </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> was equally used in more than 50% of patients in <z:hpo ids='HP_0000001'>all</z:hpo> classes of <z:mp ids='MP_0002055'>diabetes</z:mp> duration </plain></SENT>
<SENT sid="6" pm="."><plain>The use of <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> was significantly (p &lt; 0.001) increased from 25% in patients with a <z:mp ids='MP_0002055'>diabetes</z:mp> duration of less than 3 years to more than 40% in subjects with a disease duration of longer than 15 years </plain></SENT>
<SENT sid="7" pm="."><plain>The prescription of <z:chebi fb="0" ids="50864">glitazones</z:chebi> was significantly (p = 0.02) augmented with increasing <z:mp ids='MP_0002055'>diabetes</z:mp> duration </plain></SENT>
<SENT sid="8" pm="."><plain>DPP-4 inhibitors were used in more than 5% of patients with a maximum of 13% in subjects with a <z:mp ids='MP_0002055'>diabetes</z:mp> duration of 4-9 years (p &lt; 0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>The mean HbA1c was below 7.5% in <z:hpo ids='HP_0000001'>all</z:hpo> classes and was significantly (p &lt; 0.01) the lowest with 7.0 ± 1.2% in patients with the shortest <z:mp ids='MP_0002055'>diabetes</z:mp> duration when compared to <z:hpo ids='HP_0000001'>all</z:hpo> other categories </plain></SENT>
<SENT sid="10" pm="."><plain><z:mp ids='MP_0002055'>Diabetes</z:mp> Care Austria yielded representative data for <z:mp ids='MP_0002055'>diabetes</z:mp> therapy of type 2 diabetic patients treated by general practitioners </plain></SENT>
<SENT sid="11" pm="."><plain><z:mp ids='MP_0002055'>Diabetes</z:mp> treatment was successful, as proven by a mean HbA1c value of 7.2% </plain></SENT>
<SENT sid="12" pm="."><plain>An insulin therapy was initialised late, but was nevertheless effective as shown by comparable HbA1c values in patients with a <z:mp ids='MP_0002055'>diabetes</z:mp> duration of 4 to more than 15 years </plain></SENT>
</text></document>